- IP hearings this week
- IP trials
- IP Judicial review hearings
- IP appeals at the Federal Court of Appeal
(As published on the Federal Court and Federal Court of Appeal websites on Mar 20, 2023 at 00:00:00)
This week in IP
| Date | File No. | Type | Name | Location | Length |
| Mar 20, 2023 | T-1168-21 | M | Dr. Reddy's Laboratories Ltd. Et Al V. Janssen Inc, Et Al (PMNOC - Section 8 - Abiraterone*) | Toronto | 3 h |
| Mar 20, 2023 | T-1838-22 | M | Amgen Canada Inc. Et Al. V. Sandoz Canada Inc. (Patent - Carfilzomib*) | Toronto | 2 h |
| Mar 21, 2023 | T-1844-22 | JR | Tweak-d Inc. V. Attorney General Of Canada (Trade Mark - JR) | Toronto | 3 h |
| Mar 21, 2023 | T-2627-22 | CMC | Janssen Inc. V. The Minister Of Health & Agc (Patent) | Toronto | 30 m |
| Mar 21, 2023 | T-481-23 | MIIN | Lola Sheppard, Dba Lateral Office Et Al V. C S Design Inc. Et Al (Copyright) | Montréal | 3 h |
| Mar 22, 2023 | T-1441-21 | TMC | Leonard B French V. The Royal Canadian Legion (dominion Command) (Copyright) | Vancouver | 1 h |
| Mar 22, 2023 | T-841-21 | CMC | Rovi Guides, Inc. V. Videotron Ltd. (Patent) | Toronto | 1 h |
| Mar 23, 2023 | T-1831-22 | CMC | Boehringer Ingelheim (canada) Ltd. Et Al. V. Sandoz Canada Inc. (Patent - Empagliflozin*) | Ottawa | 30 m |
| Mar 23, 2023 | T-1842-22 | CMC | Boehringer Ingelheim (canada) Ltd. Et Al. V. Sun Pharma Canada Inc. (Patent - Empagliflozin*) | Ottawa | 30 m |
| Mar 23, 2023 | T-1331-22 | CMC | Amanda Chen Et Al. V. Yan Tung Evelyn Chick Et Al. (Trade Mark) | Ottawa | 1 h |
| Mar 24, 2023 | T-1004-22 | CMC | Gilead Sciences, Inc. Et Al V. Apotex Inc. (Patent - Tenofovir*) | Toronto | 1 h |
| Mar 24, 2023 | T-1006-22 | CMC | Gilead Sciences, Inc. Et Al V. Apotex Inc. (Trade Mark - Tenofovir*) | Toronto | 1 h |
Return to top.
Scheduled IP Trials
| Date | File No. | Name | Location | Length |
| Apr 12, 2023 | T-1441-21 | Leonard B French V. The Royal Canadian Legion (dominion Command) (Copyright) | Vancouver | 2 d |
| Apr 17, 2023 | T-609-20 | Wanakome Inc. V. Eric Martin Et Al. (Trade Mark) | Montréal | 10 d |
| Apr 17, 2023 | T-127-19 | Fromfroid S.a. C. 1048547 Ontario Inc. Et Al. (Patent) | Montréal | 5 d |
| May 8, 2023 | T-1924-17 | Bell Canada Et Al V. Watchnsavenow Inc. Et Al (Copyright) | Toronto | 10 d |
| Jun 5, 2023 | T-1168-21 | Dr. Reddy's Laboratories Ltd. Et Al V. Janssen Inc, Et Al (PMNOC - Section 8 - Abiraterone*) | Toronto | 10 d |
| Jun 5, 2023 | T-1966-21 | Bausch Health Ireland Ltd Et Al V. Apotex Inc. (Patent - Efinaconazole*) | Montréal | 8 d |
| Jun 5, 2023 | T-379-21 | Molo Design, Ltd. V. Chanel Canada Ulc Et Al. (Patent) | Montréal | 10 d |
| Jun 19, 2023 | T-607-21 | Apotex Inc. V. Janssen Inc. Et Al. (PMNOC - Section 8 - Abiraterone*) | Toronto | 10 d |
| Jun 19, 2023 | T-1966-21 | Bausch Health Ireland Ltd Et Al V. Apotex Inc. (Patent - Efinaconazole*) | Montréal | 2 d |
| Jun 26, 2023 | T-17-16 | Ducks Lane Ltd. Et Al V. Outfront Media Llc Et Al (Trade Mark) | Toronto | 5 d |
| Jul 10, 2023 | T-1472-21 | Pharmacyclics Llc Et Al. V. Natco Pharma (canada) Inc. (Patent - Ibrutinib*) | Toronto | 15 d |
| Jul 10, 2023 | T-1475-21 | Pharmacyclics Llc Et Al. V. Natco Pharma (canada) Inc. (Patent - Ibrutinib*) | Toronto | 15 d |
| Sep 11, 2023 | T-1962-21 | Bausch Health Ireland Ltd Et Al V. Apotex Inc. (Patent - Efinaconazole*) | Toronto | 5 d |
| Sep 11, 2023 | T-1994-21 | Allergan, Inc. Et Al. V. Juno Pharmaceuticals Corp. (Patent - Bimatoprost*) | Toronto | 10 d |
| Sep 11, 2023 | T-1488-20 | Steelhead Lng (aslng) Ltd Et Al. V. Seven Gens Energy Ltd, Rockies Lng Et Al (Patent) | Toronto | 10 d |
| Sep 18, 2023 | T-1686-18 | Wheel Monitor Inc. V. Cleral Inc. Et Al (Patent) | Toronto | 7 d |
| Sep 21, 2023 | T-1962-21 | Bausch Health Ireland Ltd Et Al V. Apotex Inc. (Patent - Efinaconazole*) | Toronto | 2 d |
| Sep 25, 2023 | T-1869-21 | Bayer Inc. Et Al. V. Sandoz Canada Inc. (Patent - Riociguat*) | Toronto | 2 d |
| Oct 3, 2023 | T-1869-21 | Bayer Inc. Et Al. V. Sandoz Canada Inc. (Patent - Riociguat*) | Toronto | 4 d |
| Oct 3, 2023 | T-15-22 | Boehringer Ingleheim (canada) Ltd. Et Al. V. Pharmascience Inc. (Patent - Linagliptin*) | Toronto | 16 d |
| Oct 3, 2023 | T-343-20 | The Noco Company, Inc. V. Canadian Tire Corporation, Limited (Patent) | Toronto | 4 d |
| Oct 10, 2023 | T-1869-21 | Bayer Inc. Et Al. V. Sandoz Canada Inc. (Patent - Riociguat*) | Toronto | 4 d |
| Oct 10, 2023 | T-343-20 | The Noco Company, Inc. V. Canadian Tire Corporation, Limited (Patent) | Toronto | 4 d |
| Oct 16, 2023 | T-151-22 | Takeda Canada V. Apotex, Takeda Pharmaceutical Co & Takeda Pharma Usa (Patent - Dexlansoprazole*) | Toronto | 10 d |
| Oct 16, 2023 | T-343-20 | The Noco Company, Inc. V. Canadian Tire Corporation, Limited (Patent) | Toronto | 2 d |
| Oct 23, 2023 | T-343-20 | The Noco Company, Inc. V. Canadian Tire Corporation, Limited (Patent) | Toronto | 1 d |
| Oct 30, 2023 | T-192-22 | Novartis Pharmaceuticals Canada Inc. Et Al. V. Teva Canada Limited (Patent - Sacubitril*) | Ottawa | 10 d |
| Nov 9, 2023 | T-151-22 | Takeda Canada V. Apotex, Takeda Pharmaceutical Co & Takeda Pharma Usa (Patent - Dexlansoprazole*) | To be determined (TrialJA) | 2 d |
| Nov 20, 2023 | T-919-21 | Maoz Betser-zilevitch V. Canadian Natural Resources Ltd. (Patent) | Toronto | 5 d |
| Nov 20, 2023 | T-1386-21 | Jcai Inc. V. Wiseleap Solutions Inc. Et Al (Patent) | Ottawa | 12 d |
| Dec 1, 2023 | T-919-21 | Maoz Betser-zilevitch V. Canadian Natural Resources Ltd. (Patent) | Toronto | 1 d |
| Jan 8, 2024 | T-1004-22 | Gilead Sciences, Inc. Et Al V. Apotex Inc. (Patent - Tenofovir*) | Toronto | 13 d |
| Jan 8, 2024 | T-1006-22 | Gilead Sciences, Inc. Et Al V. Apotex Inc. (Trade Mark - Tenofovir*) | Toronto | 13 d |
| Jan 29, 2024 | T-118-19 | Unilin Beheer B.v. Et Al V. Floors@work Inc. Et Al (Patent) | Toronto | 13 d |
| Jan 29, 2024 | T-802-20 | Eis Inc. V. Wow Tech Canada Ltd. (Patent) | Ottawa | 10 d |
| Feb 5, 2024 | T-1004-22 | Gilead Sciences, Inc. Et Al V. Apotex Inc. (Patent - Tenofovir*) | Toronto | 2 d |
| Feb 5, 2024 | T-1006-22 | Gilead Sciences, Inc. Et Al V. Apotex Inc. (Trade Mark - Tenofovir*) | Toronto | 2 d |
| Feb 12, 2024 | T-997-22 | Janssen Pharmaceutica N. V. V. Apotex Inc. (Patent - Rilpivirine*) | Toronto | 7 d |
| Feb 12, 2024 | T-953-17 | The Estate Of Vivian Maier V. Stephen M.bulger Et Al. (Copyright) | Toronto | 2 d |
| Feb 15, 2024 | T-953-17 | The Estate Of Vivian Maier V. Stephen M.bulger Et Al. (Copyright) | Toronto | 2 d |
| Feb 22, 2024 | T-118-19 | Unilin Beheer B.v. Et Al V. Floors@work Inc. Et Al (Patent) | Toronto | 1.2 d |
| Feb 22, 2024 | T-953-17 | The Estate Of Vivian Maier V. Stephen M.bulger Et Al. (Copyright) | Toronto | 2 d |
| Feb 29, 2024 | T-997-22 | Janssen Pharmaceutica N. V. V. Apotex Inc. (Patent - Rilpivirine*) | Toronto | 2 d |
| Mar 4, 2024 | T-1241-22 | Bayer Inc. Et Al V. Bgp Pharma Ulc Et Al (Patent - Aflibercept*) | Toronto | 10 d |
| Mar 4, 2024 | T-1484-22 | Gilead Sciences, Inc. Et Al. V. Jamp Pharma Corporation (Patent - Tenofovir*) | Toronto | 10 d |
| Mar 4, 2024 | T-1607-22 | Gilead Sciences, Inc. Et Al. V. Jamp Pharma Corporaton (Patent - Tenofovir*) | Toronto | 10 d |
| Mar 11, 2024 | T-1175-22 | Boehringer Ingelheim (canada) Ltd. Et Al V. Apotex Inc. (Patent) | Toronto | 13 d |
| Mar 11, 2024 | T-1176-22 | Boehringer Ingelheim (canada) Ltd. Et Al V. Apotex Inc. (Patent - Linagliptin*) | Toronto | 13 d |
| Mar 11, 2024 | T-1178-22 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Apotex Inc. (Patent - Linagliptin*) | Toronto | 13 d |
| Mar 11, 2024 | T-1181-22 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Apotex Inc. (Patent - Linagliptin*) | Toronto | 13 d |
| Mar 11, 2024 | T-1187-22 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Apotex Inc. (Patent - Linagliptin*) | Toronto | 13 d |
| Mar 11, 2024 | T-1188-22 | Boehringer Ingelheim (canada) Ltd. Et Al V. Apotex Inc. (Patent - Linagliptin*) | Toronto | 13 d |
| Mar 18, 2024 | T-1121-22 | Janssen Inc. Et Al V. Apotex Inc. (Patent - Paliperidone*) | Toronto | 5 d |
| Mar 18, 2024 | T-1122-22 | Janssen Inc. Et Al V. Apotex Inc. (Patent - Paliperidone*) | Toronto | 5 d |
| Mar 18, 2024 | T-1248-22 | Janssen Inc. Et Al. V. Apotex Inc. (Patent - Paliperidone*) | Toronto | 5 d |
| Mar 18, 2024 | T-1249-22 | Janssen Inc. Et Al. V. Apotex Inc. (Patent - Paliperidone*) | Toronto | 5 d |
| Mar 25, 2024 | T-1484-22 | Gilead Sciences, Inc. Et Al. V. Jamp Pharma Corporation (Patent - Tenofovir*) | Toronto | 2 d |
| Mar 25, 2024 | T-1607-22 | Gilead Sciences, Inc. Et Al. V. Jamp Pharma Corporaton (Patent - Tenofovir*) | Toronto | 2 d |
| Apr 4, 2024 | T-1175-22 | Boehringer Ingelheim (canada) Ltd. Et Al V. Apotex Inc. (Patent) | Toronto | 2 d |
| Apr 4, 2024 | T-1176-22 | Boehringer Ingelheim (canada) Ltd. Et Al V. Apotex Inc. (Patent - Linagliptin*) | Toronto | 2 d |
| Apr 4, 2024 | T-1178-22 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Apotex Inc. (Patent - Linagliptin*) | Toronto | 2 d |
| Apr 4, 2024 | T-1181-22 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Apotex Inc. (Patent - Linagliptin*) | Toronto | 2 d |
| Apr 4, 2024 | T-1187-22 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Apotex Inc. (Patent - Linagliptin*) | Toronto | 2 d |
| Apr 4, 2024 | T-1188-22 | Boehringer Ingelheim (canada) Ltd. Et Al V. Apotex Inc. (Patent - Linagliptin*) | Toronto | 2 d |
| Apr 8, 2024 | T-1555-22 | Gilead Sciences, Inc. Et Al. V. Natco Pharma (canada), Inc. (Patent - Tenofovir*) | Toronto | 9 d |
| Apr 8, 2024 | T-1556-22 | Gilead Sciences, Inc. Et Al. V. Natco Pharma (canada) Inc. (Patent - Tenofovir*) | Toronto | 9 d |
| Apr 29, 2024 | T-1555-22 | Gilead Sciences, Inc. Et Al. V. Natco Pharma (canada), Inc. (Patent - Tenofovir*) | Toronto | 1 d |
| Apr 29, 2024 | T-1556-22 | Gilead Sciences, Inc. Et Al. V. Natco Pharma (canada) Inc. (Patent - Tenofovir*) | Toronto | 1 d |
| Apr 29, 2024 | T-1174-21 | Bauer Hockey Ltd. V. Bladetech Hockey Inc. (Patent) | Montréal | 10 d |
| Apr 29, 2024 | T-1769-21 | Bauer Hockey Ltd. V. Flare Skate Blade Ltd. (Patent) | Montréal | 10 d |
| May 6, 2024 | T-1563-22 | Boehringer Ingelheim(canada) Ltd Et Al V. Jamp Pharma Corp. (Patent - Nintedanib*) | Toronto | 10 d |
| May 7, 2024 | T-1750-22 | Actelion Pharmaceuticals Ltd Et Al. V. Sandoz Canada Inc. (Patent - Selexipag*) | Toronto | 9 d |
| May 13, 2024 | T-2029-22 | Bayer Inc Et Al V. Bgp Pharma Ulc(viatris Canada) (Patent - Aflibercept*) | Toronto | 5 d |
| May 24, 2024 | T-1750-22 | Actelion Pharmaceuticals Ltd Et Al. V. Sandoz Canada Inc. (Patent - Selexipag*) | Toronto | 1 d |
| May 27, 2024 | T-1838-22 | Amgen Canada Inc. Et Al. V. Sandoz Canada Inc. (Patent - Carfilzomib*) | Toronto | 12 d |
| May 27, 2024 | T-1563-22 | Boehringer Ingelheim(canada) Ltd Et Al V. Jamp Pharma Corp. (Patent - Nintedanib*) | Toronto | 2 d |
| May 27, 2024 | T-1831-22 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Sandoz Canada Inc. (Patent - Empagliflozin*) | To be determined (TrialJA) | 20 d |
| May 27, 2024 | T-1842-22 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Sun Pharma Canada Inc. (Patent - Empagliflozin*) | To be determined (TrialJA) | 20 d |
| Jun 14, 2024 | T-1838-22 | Amgen Canada Inc. Et Al. V. Sandoz Canada Inc. (Patent - Carfilzomib*) | Toronto | 6 d |
| Jun 17, 2024 | T-1449-20 | Proslide Technology, Inc. V. Whitewater West Industries, Ltd. (Patent) | To be determined (TrialJA) | 10 d |
| Jun 24, 2024 | T-2251-22 | Bausch Health Ireland Ltd. Et Al V. Pharmascience Inc. (Patent - Efinaconazole*) | To be determined (TrialJA) | 5 d |
| Jun 25, 2024 | T-1831-22 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Sandoz Canada Inc. (Patent - Empagliflozin*) | To be determined (TrialJA) | 3 d |
| Jun 25, 2024 | T-1842-22 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Sun Pharma Canada Inc. (Patent - Empagliflozin*) | To be determined (TrialJA) | 3 d |
| Jul 2, 2024 | T-1838-22 | Amgen Canada Inc. Et Al. V. Sandoz Canada Inc. (Patent - Carfilzomib*) | Toronto | 2 d |
| Jul 3, 2024 | T-1449-20 | Proslide Technology, Inc. V. Whitewater West Industries, Ltd. (Patent) | To be determined (TrialJA) | 3 d |
| Jul 4, 2024 | T-2251-22 | Bausch Health Ireland Ltd. Et Al V. Pharmascience Inc. (Patent - Efinaconazole*) | To be determined (TrialJA) | 2 d |
| Jul 15, 2024 | T-2276-22 | Boehringer Ingelheim (canada) Ltd Et Al. V. Jamp Pharma Corporation (Patent - Empagliflozin*) | To be determined (TrialJA) | 10 d |
| Jul 15, 2024 | T-2318-22 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Jamp Pharma Corporation (Patent - Empagliflozin*) | To be determined (TrialJA) | 10 d |
| Aug 12, 2024 | T-2276-22 | Boehringer Ingelheim (canada) Ltd Et Al. V. Jamp Pharma Corporation (Patent - Empagliflozin*) | To be determined (TrialJA) | 10 d |
| Aug 12, 2024 | T-2318-22 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Jamp Pharma Corporation (Patent - Empagliflozin*) | To be determined (TrialJA) | 10 d |
| Aug 12, 2024 | T-2133-22 | Gilead Sciences, Inc. Et Al V. Pharmascience Inc. (Patent - Tenofovir*) | Toronto | 10 d |
| Aug 12, 2024 | T-2139-22 | Gilead Sciences, Inc. Et Al V. Pharmascience Inc. (Patent - Tenofovir*) | Toronto | 10 d |
| Aug 26, 2024 | T-2279-22 | Pharmacyclics Llc Et Al. V. Natco Pharma (canada) Inc. (Patent - Ibrutinib*) | To be determined (TrialJA) | 5 d |
| Aug 28, 2024 | T-2276-22 | Boehringer Ingelheim (canada) Ltd Et Al. V. Jamp Pharma Corporation (Patent - Empagliflozin*) | To be determined (TrialJA) | 3 d |
| Aug 28, 2024 | T-2318-22 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Jamp Pharma Corporation (Patent - Empagliflozin*) | To be determined (TrialJA) | 3 d |
| Aug 29, 2024 | T-2133-22 | Gilead Sciences, Inc. Et Al V. Pharmascience Inc. (Patent - Tenofovir*) | Toronto | 2 d |
| Aug 29, 2024 | T-2139-22 | Gilead Sciences, Inc. Et Al V. Pharmascience Inc. (Patent - Tenofovir*) | Toronto | 2 d |
| Sep 3, 2024 | T-2279-22 | Pharmacyclics Llc Et Al. V. Natco Pharma (canada) Inc. (Patent - Ibrutinib*) | To be determined (TrialJA) | 4 d |
| Sep 9, 2024 | T-2178-22 | Boehringer Ingelheim (canada) Ltd V. Accord Healthcare Inc. (Patent - Nintedanib*) | Toronto | 9 d |
| Sep 9, 2024 | T-2179-22 | Boehringer Ingelheim (canada) Ltd Et Al V. Accord Health Inc. (Patent - Nintedanib*) | Toronto | 9 d |
| Sep 13, 2024 | T-2279-22 | Pharmacyclics Llc Et Al. V. Natco Pharma (canada) Inc. (Patent - Ibrutinib*) | To be determined (TrialJA) | 1 d |
| Sep 27, 2024 | T-2178-22 | Boehringer Ingelheim (canada) Ltd V. Accord Healthcare Inc. (Patent - Nintedanib*) | Toronto | 1 d |
| Sep 27, 2024 | T-2179-22 | Boehringer Ingelheim (canada) Ltd Et Al V. Accord Health Inc. (Patent - Nintedanib*) | Toronto | 1 d |
| Oct 1, 2024 | T-192-23 | Boehringer Ingelheim (canada) Ltd Et Al V. Laboratoire Riva Inc. (Patent - Linagliptin*) | Toronto | 9 d |
| Oct 1, 2024 | T-191-23 | Boehringer Ingelheim (canada) Ltd Et Al V. Laboratoire Riva Inc. (Patent) | Toronto | 9 d |
| Oct 1, 2024 | T-193-23 | Boehringer Ingelheim (canada) Ltd Et Al V. Laboratoire Riva Inc. (Patent - Linagliptin*) | Toronto | 9 d |
| Oct 1, 2024 | T-194-23 | Boehringer Ingelheim (canada) Ltd Et Al V. Laboratoire Riva Inc (Patent - Linagliptin*) | Toronto | 9 d |
| Oct 1, 2024 | T-195-23 | Boehringer Ingelheim (canada) Ltd Et Al V. Laboratoire Riva Inc (Patent - Linagliptin*) | Toronto | 9 d |
| Oct 1, 2024 | T-196-23 | Boehringer Ingelheim (canada) Ltd. Et Al V. Laboratoire Riva Inc. (Patent - Linagliptin*) | Toronto | 9 d |
| Oct 1, 2024 | T-197-23 | Boehringer Ingelheim (canada)ltd Et Al V. Laboratoire Riva Inc. (Patent - Linagliptin*) | Toronto | 9 d |
| Oct 21, 2024 | T-192-23 | Boehringer Ingelheim (canada) Ltd Et Al V. Laboratoire Riva Inc. (Patent - Linagliptin*) | Toronto | 4 d |
| Oct 21, 2024 | T-191-23 | Boehringer Ingelheim (canada) Ltd Et Al V. Laboratoire Riva Inc. (Patent) | Toronto | 4 d |
| Oct 21, 2024 | T-193-23 | Boehringer Ingelheim (canada) Ltd Et Al V. Laboratoire Riva Inc. (Patent - Linagliptin*) | Toronto | 4 d |
| Oct 21, 2024 | T-194-23 | Boehringer Ingelheim (canada) Ltd Et Al V. Laboratoire Riva Inc (Patent - Linagliptin*) | Toronto | 4 d |
| Oct 21, 2024 | T-195-23 | Boehringer Ingelheim (canada) Ltd Et Al V. Laboratoire Riva Inc (Patent - Linagliptin*) | Toronto | 4 d |
| Oct 21, 2024 | T-196-23 | Boehringer Ingelheim (canada) Ltd. Et Al V. Laboratoire Riva Inc. (Patent - Linagliptin*) | Toronto | 4 d |
| Oct 21, 2024 | T-197-23 | Boehringer Ingelheim (canada)ltd Et Al V. Laboratoire Riva Inc. (Patent - Linagliptin*) | Toronto | 4 d |
| Oct 21, 2024 | T-269-23 | Novartis Pharmaceuticals Canada Inc. Et Al. V. Apotex Inc. (Patent - Nilotinib*) | To be determined (TrialJA) | 8 d |
| Oct 21, 2024 | T-2307-22 | Astrazeneca Canada Inc. Et Al V. Pharmascience Inc. (Patent - Dapagliflozin*) | To be determined (TrialJA) | 9 d |
| Oct 30, 2024 | T-192-23 | Boehringer Ingelheim (canada) Ltd Et Al V. Laboratoire Riva Inc. (Patent - Linagliptin*) | Toronto | 2 d |
| Oct 30, 2024 | T-191-23 | Boehringer Ingelheim (canada) Ltd Et Al V. Laboratoire Riva Inc. (Patent) | Toronto | 2 d |
| Oct 30, 2024 | T-193-23 | Boehringer Ingelheim (canada) Ltd Et Al V. Laboratoire Riva Inc. (Patent - Linagliptin*) | Toronto | 2 d |
| Oct 30, 2024 | T-194-23 | Boehringer Ingelheim (canada) Ltd Et Al V. Laboratoire Riva Inc (Patent - Linagliptin*) | Toronto | 2 d |
| Oct 30, 2024 | T-195-23 | Boehringer Ingelheim (canada) Ltd Et Al V. Laboratoire Riva Inc (Patent - Linagliptin*) | Toronto | 2 d |
| Oct 30, 2024 | T-196-23 | Boehringer Ingelheim (canada) Ltd. Et Al V. Laboratoire Riva Inc. (Patent - Linagliptin*) | Toronto | 2 d |
| Oct 30, 2024 | T-197-23 | Boehringer Ingelheim (canada)ltd Et Al V. Laboratoire Riva Inc. (Patent - Linagliptin*) | Toronto | 2 d |
| Nov 6, 2024 | T-269-23 | Novartis Pharmaceuticals Canada Inc. Et Al. V. Apotex Inc. (Patent - Nilotinib*) | To be determined (TrialJA) | 2 d |
| Nov 8, 2024 | T-2307-22 | Astrazeneca Canada Inc. Et Al V. Pharmascience Inc. (Patent - Dapagliflozin*) | To be determined (TrialJA) | 1 d |
| Nov 12, 2024 | T-1477-22 | Pfizer Canada Ulc And Pfizer Inc. V. Amgen Research (munich) Gmbh And Amgen (Patent - Elranatamab*) | Toronto | 9 d |
| Nov 27, 2024 | T-1477-22 | Pfizer Canada Ulc And Pfizer Inc. V. Amgen Research (munich) Gmbh And Amgen (Patent - Elranatamab*) | Toronto | 1 d |
| Nov 28, 2024 | T-1766-22 | Bayer Inc. Et Al V. Bgp Pharma Ulc D.b.a. Viatris Canada (Patent - Aflibercept*) | Toronto | 10 d |
| Nov 28, 2024 | T-1482-22 | Bayer Inc. Et Al. V. Bgp Pharma Ulc D.b.a. Viatris Canada Et Al. (Patent - Aflibercept*) | Toronto | 10 d |
| Dec 18, 2024 | T-1766-22 | Bayer Inc. Et Al V. Bgp Pharma Ulc D.b.a. Viatris Canada (Patent - Aflibercept*) | Toronto | 2 d |
| Dec 18, 2024 | T-1482-22 | Bayer Inc. Et Al. V. Bgp Pharma Ulc D.b.a. Viatris Canada Et Al. (Patent - Aflibercept*) | Toronto | 2 d |
Return to top.
Scheduled Judicial Review Hearings
| Date | File No. | Name | Type | Location | Length |
| Mar 21, 2023 | T-1844-22 | Tweak-d Inc. V. Attorney General Of Canada | Trade Mark - Appeal of a decision of the Registrar | Toronto | 3 h |
| Mar 28, 2023 | T-1424-22 | Jeff Toth Et Al. V. Minister Of Health - Psilocybin* | S. 18.1 Application for Judicial Review | Ottawa | 1 d |
| Apr 4, 2023 | T-1173-21 | Lazare V.t. Boubala, Lazare's Bbq House Inc. V. Mussa Siddiqui Khwaja | Copyright Infringement [Applications] | Ottawa | 3 h |
| Apr 13, 2023 | T-2081-22 | Les Industries Certico Inc. V. Mastrandrea Commercial Bakeries Ltd Et Al | Trade Mark - Appeal of a decision of the Registrar | Montréal | 2 h |
| Apr 17, 2023 | T-1664-22 | Novartis Ag Et Al V. Biogen, Inc. Et Al | Trade Mark Infringement | Toronto | 2 d |
| May 17, 2023 | T-1794-22 | Jean-louis Vill C. Bell Canada | Trade Mark - Appeal of a decision of the Registrar | Montréal | 1 d |
| May 25, 2023 | T-2627-22 | Janssen Inc. V. The Minister Of Health & Agc | Patent - Appeal of a Decision of Commissioner | Toronto | 1 d |
| Jun 6, 2023 | T-1483-22 | Patagonia Inc V. Labatt Brewing Co. Ltd. | Trade Mark Expungement | Ottawa | 4 h |
| Jun 27, 2023 | T-2001-21 | Biologische Heilmittel Heel Gmbh V. Barrette Legal Inc. | Trade Mark - Appeal of a decision of the Registrar | Ottawa | 2 h |
| Nov 15, 2023 | T-1311-19 | Apotex Inc. V. Minister Of Health Et Al | Access to Information | Toronto | 2 d |
| Jan 18, 2024 | T-132-22 | Apotex Inc. V. Minister Of Health Et Al. | Access to Information | Toronto | 1 d |
Return to top.
Scheduled IP Appeals
| Date | File No. | Name | Type | Location | Length |
| Mar 28, 2023 | A-129-22 | Voltage Holdings, Llc V. Doe #1 Et Al | Appeal (S.27 - Interloc.) - Others [from T-513-18 - Copyright Infringement [Actions]] | Toronto | 3 h |
* Medicinal ingredients are based on automated analysis and should not be relied upon.
Return to top.